Stocktoria

ANGIODYNAMICS INC ANGO

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2004-05-27 · LEI

ANGIODYNAMICS INC (ANGO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $320.2M at a -11.5% net margin.

Chart by TradingView
34/100
Stocktoria Quality Score · grade D
5/9
Piotroski F — financial health
-1.82
Altman Z″ — distress risk · distress
Dividend yield · no dividend
-3.09
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 7 5 2 4 3 4 4 5 4 2017201820192020202120222023202420252026
Altman Z″
3.41 4.42 4.99 2.11 3.57 3.01 1.62 -4.09 -1.82 -2.65 2017201820192020202120222023202420252026

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$15.75 as of 2026-08-01 · +53.5% 1y
$10.26$15.7552-wk

Beneish M-score: -3.09 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$554M
Net margin 5y avg-21.5%
Return on equity 5y avg-30%
Beta0.36
Employees675

Analyst price target

$18.00 +14.3% vs last
· 4 analysts
target range $16.00 – $24.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$239,532 on the open market · 3 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · down

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 63%
Net marginstronger than 40%
Return on equitystronger than 42%
Revenue growthstronger than 62%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.329
Retained earnings / assets-1.532
EBIT / assets-0.143
Equity / liabilities1.883

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ANGOANGIODYNAMICS INC5/9-1.82+9.5%
TCMDTACTILE SYSTEMS TECHNOLOGY INC7/98.5235.8+12.5%
PRCTPROCEPT BioRobotics Corp3/92.18+37.2%
SKINSkinHealth Systems Inc.6/9-1.89-10%
LMATLEMAITRE VASCULAR INC6/98.1837.9+13.5%
KIDSORTHOPEDIATRICS CORP4/92.67+15.4%
CERSCERUS CORP4/9-13.54+16.1%

All Manufacturing companies →

About ANGIODYNAMICS INC

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

FAQ

Is ANGO financially healthy?

ANGIODYNAMICS INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does ANGO pay a dividend?

No, ANGIODYNAMICS INC does not currently pay a dividend.

How profitable is ANGO?

In FY2025, ANGIODYNAMICS INC had a net margin of -11.5% and a return on equity of -21.5%.

Is ANGO overvalued or undervalued?

ANGIODYNAMICS INC trades at about 9.6× trailing earnings — below its 10-year norm (10-year range 12.0×–233.3×, median 115.8×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for ANGO?

The average Wall-Street price target for ANGIODYNAMICS INC is $18.00, about 14.3% above the recent price, from 4 analysts.

Is ANGO a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ANGIODYNAMICS INC: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.